Abstract:Abstract Background China is the second highest pulmonary tuberculosis (PTB) burden country worldwide. However, retreatment of PTB has often developed resistance to at least one of the four first-line anti-TB drugs. The cure rate (approximately 50.0–73.3%) and management of retreatment of PTB in China needs to be improved. Qinbudan decoction has been widely used to treat PTB in China since the 1960s. Previously clinical studies have shown that the Qinbudan tablet (QBDT) promoted sputum-culture negative conversion and lesion absorption. However, powerful evidence from a randomized controlled clinical trial is lacking. Therefore, the aim of this study was to compare the efficacy and safety of QBDT as an adjunct therapy for retreatment of PTB. Methods We conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial in China. People diagnosed with PTB were enrolled who received previous anti-TB treatment from April 2011 to March 2013. The treatment group received an anti-TB regimen and QBDT, and the control group was administered an anti-TB regimen plus placebo. Anti-TB treatment options included isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin for 2 months (2HRZES), followed by isoniazid, rifampicin, ethambutol for 6 months (6HRE), daily for 8 months. Primary outcome was sputum-culture conversion using the MGIT 960 liquid medium method. Secondary outcomes included lung lesion absorption and cavity closure. Adverse events and reactions were observed after treatment. A structured questionnaire was used to record demographic information and clinical symptoms of all subjects. Data analysis was performed by SPSS 25.0 software in the full analysis set (FAS) population. Results One hundred eighty-one cases of retreatment PTB were randomly divided into two groups: the placebo group (88 cases) and the QBDT group (93 cases). A total of 166 patients completed the trial and 15 patients lost to follow-up. The culture conversion rate of the QBDT group and placebo group did not show a noticeable improvement by using the covariate sites to correct the rate differences (79.6% vs 69.3%; rate difference = 0.10, 95% confidence interval (CI): - 0.02–0.23; F = 2.48, P = 0.12) after treatment. A significant 16.6% increase in lesion absorption was observed in the QBDT group when compared with the placebo group (67.7% vs 51.1%; rate difference = 0.17, 95% CI: 0.02–0.31; χ 2 = 5.56, P = 0.02). The intervention and placebo group did not differ in terms of cavity closure (25.5% vs 21.1%; rate difference = 0.04, 95% CI: - 0.21–0.12; χ 2 = 0.27, P = 0.60). Two patients who received chemotherapy and combined QBDT reported pruritus/nausea and vomiting. Conclusions No significant improvement in culture conversion was observed for retreatment PTB with traditional Chinese medicine plus standard anti-TB regimen. However, QBDT as an adjunct therapy significantly promoted lesion absorption, thereby reducing lung injury due to Mycobacterium tuberculosis infection. Trial registration This trial is registered at ClinicalTrials.gov, NCT02313610 .

Animal Experiment and Clinical Preliminary Application of Percutaneous 70% Ethanol Injection Therapy in Multi-Drug Resistant Pulmonary Tuberculosis

A Study on the Treatment of Local and Acupoint Irradiation with Low-Energy He-Ne Laser for Pulmonary Tuberculosis Cavity

Experimental research of percutaneous intrahepatic ethanol injection under CT guidance

The Study of the Effect of the Treatment of Multi-Drug Resistent Pulmonary Tuberculosis with with Steam Inhalations and Chemotherapy

Experimental research of percutaneous ethanol therapy with different concentration injections on hepatic vx2 tumor of rabbits

Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis

Intrabiliary Radiofrequency-Enhanced Local Chemotherapeutic Deposit in Bile Duct Walls Using a Needle-Integrated Balloon Catheter: A Feasibility Study on Survival Pigs

A controlled clinical study of long course chemotherapy regimens combined with immunopotentiator in the treatment of multi-drug resistant pulmonary tuberculosis

Investigation for prognosis of hospitalized patients with pulmonary tuberculosis and analysis for related factors

Treatment of primary liver cancer with alcohol injection

CT guided percutaneous ethanol injection of transplanted liver VX2 tumor on rabbits

Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China.

Hepatoprotective effect of diammonium glycyrrhizinate in the treatment of pulmonary tuberculosis

The diagnosis and treatment of tuberculosis in orthotopic liver transplant patients with a review of literature

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Improvement Cues of Lesion Absorption Using the Adjuvant Therapy of Traditional Chinese Medicine Qinbudan Tablet for Retreatment Pulmonary Tuberculosis with Standard Anti-Tuberculosis Regimen

Clinical Study of Different Treatment Methods for Tuberculous Pleuritis Complicated with Pleural Tuberculoma

Analysis of Clinical Symptoms Improvement in Treatment of Severe Pneumonia Caused by Multi-drug Resistant Bacterial Infection by Bronchoscopy Alveolar Lavage

Curative Effect and Cost-effectiveness of Traditional Chinese Medicine and Immunomodulator in Adjuvant Treatment of Retreatment Pulmonary Tuberculosis

Allogeneic Vγ9Vδ2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An Open-Label, Single-Arm Pilot Study in Patients With Multidrug-Resistant Tuberculosis

Surgical Treatment of Multi-Drug Resistant Pulmonary Tuberculosis in 188 Cases